Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

which is traditionally treated with a stem-cell transplant. Around 5,500 people are diagnosed with DLBCL in the UK each year, ...

Disclosed on November 13, Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals JAZZ -2.13% Get Free Report , ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...

Aileen Lamb, who was given the all clear after fighting acute myeloid leukaemia, was welcomed the approval of Axicabtagene ciloleucel (axi-cel). The drug is used for adults diagnosed with diffuse ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and ... across ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...